Immunogen news
The company said it will pay $31.26 in cash for each ImmunoGen share. That amounts to a 95% premium on the stock's closing closing price Wednesday of $16.06. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth.May 4, 2023 · Prior to yesterday's news, ImmunoGen stock had been trading at a value of ~$4 - which is about the average across the past 5 year period. Shares ended the day trading at $12.2 - their highest ... ImmunoGen will release figures for the most recent quarter on November 2. Forecasts of 13 analysts expect earnings of $0.044 per share compared to losses of $0.310 per share from the same quarter ...
Did you know?
Nov 15, 2022 · The FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ:IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian ... In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen (IMGN – Research Report), with a price target of $15.00.The company’s shares closed ...ImmunoGen's stock has rocketed 225.2% year to date through Friday, while the S&P 500 has tacked on 14.8%. -Tomi Kilgore . This content was created by MarketWatch, which is operated by Dow Jones ...Find real-time IMGN - ImmunoGen Inc stock quotes, company profile, news and forecasts from CNN Business. Shares of Waltham, Massachusetts.-based ImmunoGen Inc. soared more than 80% to top $29 in mid-morning trading Thursday. North Chicago, Illinois-based AbbVie Inc. stock was up 2% to $141.26 while ...Name. Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a ...29.33. +13.27. +82.63%. Shares of ImmunoGen (IMGN), a biotechnology company focused on cancer treatments, surged Thursday afternoon on news that pharmaceutical giant AbbVie (ABBV) plans to acquire ...INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan 781-895-0600 [email protected] MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600 [email protected] OR FTI Consulting ...View the latest Immunogen Inc. (IMGN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get the latest ImmunoGen Inc. (IMGN) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Update 08:14 AM EST: Adds latest share price moves. Per the terms, the North Chicago, Illinois-based pharma giant will acquire all outstanding ImmunoGen (IMGN) shares for $31.26 per share in cash ...Nov 30, 2023 · Photo: Brian L. Frank for The Wall Street Journal. Drug company AbbVie has agreed to buy biotech ImmunoGen for $10.1 billion in a new bet on one of the most promising novel drug technologies for ... Jul 24, 2023 · ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and ... In other ImmunoGen news, SVP Stacy Ann Coen soFind the latest news headlines from ImmunoGe CERE. Cerevel Therapeutics Holdings Inc. 25.38. UNCH. UNCH. Get ImmunoGen Inc (IMGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.ImmunoGen’s stock soared 81% in morning trading, putting it on track for the highest close since November 2000. AbbVie shares gained 0.9%. Under the terms of the agreement, AbbVie will pay $31. ... WALTHAM, Mass., June 09, 2023--ImmunoGen Inc. (Nasda ImmunoGen (IMGN) experiences a 6.5% surge amid speculation of a potential takeover by a European pharmaceutical company, with short interest at 9.4%.In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on ImmunoGen (IMGN – Research Report), with a price target of $15.00.The company’s shares closed ... The company said it will pay $31.26 in cash for each
Dec 1, 2023 · AbbVie announced on Thursday its intent to buy ImmunoGen for $10.1 billion, or $31.26 per share, nearly double ImmunoGen’s share price of $16.06 at market close the day before the deal. More AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying its oncology pipeline and potentially transforming its cancer care business. ImmunoGen's antibody-drug ...May 3, 2023 · May. 3, 2023, 06:56 AM. (RTTNews) - ImmunoGen Inc. (IMGN) reported positive top-line data from the Phase 3 confirmatory MIRASOL trial evaluating the safety and efficacy of ELAHERE compared to ... Nov 30, 2023 · November 30, 2023 at 5:16 AM PST. Listen. 1:20. AbbVie Inc. agreed to acquire ImmunoGen Inc. for a total equity value of $10.1 billion, delivering the biotech company’s Elahere cancer drug to ... 5 days ago ... Ropes & Gray advised ImmunoGen in the deal that Bloomberg News said is aimed at gaining access to come of the hottest new drugs in the growing ...
May 3 (Reuters) - ImmunoGen Inc (IMGN.O) shares more than doubled on Wednesday after the company said its experimental ovarian cancer drug helped extend …ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer.…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. AbbVie is buying ImmunoGen in a deal valued . Possible cause: WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 4, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a lea.
Harsh is the Lead News Editor at Invezz, where he handles end-to-end news operations. ... AbbVie’s offer of $31.26 per share represents a substantial 94.6% premium to ImmunoGen’s last trading ...Nov 30, 2023 · AbbVie to Acquire ImmunoGen in $10 Billion Deal. ImmunoGen stock was rising Thursday following an announcement that biopharmaceutical company AbbVie has agreed to buy the cancer treatment ...
The need-to-know this morning. • Abbvie said it would acquire ImmunoGen, a maker of cancer drugs, for $10.1 billion. ImmunoGen is being acquired for $31.26 per share, or a 95% premium to its ...Dec 1, 2023 · Get the latest news and real-time alerts from ImmunoGen, Inc. (IMGN) stock at Seeking Alpha. INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan 781-895-0600 [email protected] MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600 [email protected] OR FTI Consulting ...
By MarketNewsVideo Former Contributor. Jan 16, 201 ImmunoGen stock is taking off on news that AbbVie is acquiring all outstanding shares of IMGN in a $10.1 billion acquisition deal.More From InvestorPlace Musk’s “Project Omega” May Be Set to ...Shares of Immunogen are trading down 2.6% over the last 24 hours, at $14.97 per share. A move to $18.00 would account for a 20.24% increase from the current share price. About Immunogen WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NNov 6, 2023 · Jonathan Chang’s Hold rating for ImmunoGen’s stock ( Dec 1, 2023 · AbbVie announced on Thursday its intent to buy ImmunoGen for $10.1 billion, or $31.26 per share, nearly double ImmunoGen’s share price of $16.06 at market close the day before the deal. More 5 days ago ... ImmunoGen Inc. developed the ovarian cancer drug Elahe WALTHAM, Mass., June 09, 2023--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an ... Updated May 03, 2023, 5:39 pm EDT / Original May 03, 2023, 5:15 pmImmunoGen is a clinical-stage biotechnology company that focuAbbVie Pays $10.1 Billion for ImmunoGen to Expan Updated May 03, 2023, 5:39 pm EDT / Original May 03, 2023, 5:15 pm EDT. ImmunoGen ’s shares soared 136% on Wednesday after the biotech company reported “significant and clinically meaningful ...Apr 28, 2023 · Net loss for the first quarter of 2023 was $41.0 million, or $0.16 per diluted share, compared to net loss of $24.1 million, or $0.10 per diluted share, for the first quarter of 2022. ImmunoGen ... According to the current price, ImmunoGen is 98.74% away from th (RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of September 12, 2017. GAINERS... INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtn[The sizzling antibody-drug conjugate (ADC) fiNews and Insights-> Markets-> Companies-> Cryptocu From Last Week: ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug IMGN Price Action: ImmunoGen shares were up 93.5% at $10.06 at time of publication ...INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan 781-895-0600 [email protected] MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600 [email protected] OR FTI Consulting ...